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Recognition and eradication of infected cells by cytotoxic T lymphocytes is a key defense
mechanism against intracellular pathogens. High-throughput definition of HLA class I-
associated immunopeptidomes by mass spectrometry is an increasingly important ana-
lytical tool to advance our understanding of the induction of T-cell responses against
pathogens such as HIV-1. We utilized a liquid chromatography tandem mass spectrom-
etry workflow including de novo-assisted database searching to define the HLA class
I-associated immunopeptidome of HIV-1-infected human cells. We here report for the
first time the identification of 75 HIV-1-derived peptides bound to HLA class I complexes
that were purified directly from HIV-1-infected human primary CD4+ T cells and the
C8166 human T-cell line. Importantly, one-third of eluted HIV-1 peptides had not been
previously known to be presented by HLA class I. Over 82% of the identified sequences
originated from viral protein regions for which T-cell responses have previously been
reported but for which the precise HLA class I-binding sequences have not yet been
defined. These results validate and expand the current knowledge of virus-specific anti-
genic peptide presentation during HIV-1 infection and provide novel targets for T-cell
vaccine development.
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Introduction
Cytotoxic T lymphocyte (CTL) mediated recognition and elimi-
nation of infected cells is a major arm of the immune response
against intracellular pathogens [1]. Typically, CTLs are CD8+ T
lymphocytes, which recognize virus-derived peptides presented on
the surface of infected cells in complex with HLA class I molecules
[2, 3]. Aside from innate and humoral responses, induction of
effective CTL responses by vaccination is likely required for pro-
tection particularly against pathogens that replicate intracellularly
and for which induction of sterilizing immunity is difficult. Exam-
ples include the causative agents of malaria, tuberculosis, and
acquired immunodeficiency syndrome (HIV/AIDS).
HIV/AIDS continues to be a major global health problem [4].
There is strong evidence that CD8+ T cells contribute to the control
of acute and chronic HIV-1 infection in a major way [5]. Under-
standing the characteristics of the HLA class I-associated pep-
tidomes on the surface of HIV-1-infected cells has the potential to
crucially inform the development of effective preventive and thera-
peutic T-cell vaccines. Such improved understandingmay also pro-
vide further insights into allele-specific binding motifs and more
general phenomena such as the protective role of certain HLA
alleles [5] and factors that define T-cell immunodominance [6].
Recent advances in the technology of nanoflow liquid chro-
matography tandem mass spectrometry (LC-MS/MS) allow the
direct qualitative evaluation of HLA-associated peptidomes [7, 8].
In the context of HIV-1 infection, cells overexpressing individ-
ual viral proteins were analyzed for presentation of viral HLA-
associated peptides [9, 10] and recently, peptides were purified
from soluble HLA-A molecules secreted from a HIV-1-infected T-
cell line [11]. In each case, viral antigen was either delivered by
transfection of plasmids encoding selected HIV-1 proteins or by
continuous infection cycles of immortalized cells lines secreting
soluble HLA molecules in bioreactors. Despite the limitations of
these approaches, they yielded a number of important observa-
tions, including identification of a considerable number of pre-
viously unmapped, putative T-cell epitopes, and highlighting the
paucity of HIV-1 peptides within the complex immunopeptidome
of the HIV-1-infected cell.
Here, we used an immunopurification protocol to specifically
isolate and identify a large number of peptides bound to HLA
class I complexes from HIV-1-infected primary CD4+ T cells and
C8166 cells (a cell line efficiently infected by HIV-1) utilizing an
LC-MS/MS analysis workflow.
Results
Characterization of the HLA class I-associated
immunopeptidome of HIV-1-infected cells
To prepare infected cells, the human immortalized cell line
C8166 (A*01:01/01:01, B*08:01/44:02; C*05:01/07:01) or pri-
mary CD8+ cell-depleted PBMC from three HIV-1-uninfected indi-
viduals (C6 of A*24:02/29:02, B*35:03/45:01, C*04:01/06:02;
C7 of A*11:01/68:01, B*07:02/27:05, C*01:02/07:02; and C8 of
A*29:02/30:04, B*41:01/44:03, C*16:01/17:01 genotypes) was
optimally infected with HIV-1 IIIB at a multiplicity of infection
(MOI) that yielded maximal infection rates of 68.2% for the cell
line and 19.8, 21.3, and 22.3% for the primary cell samples C6,
C7, and C8, respectively. Infection was estimated by an intracellu-
lar anti-p24 antigen staining [12], and approximately 108 infected
cells were used per analysis. As negative control, uninfected C8166
cells and CD8+ cell-depleted PBMC from C8 were analyzed in
parallel. Cells were lysed and a resin-linked, HLA class I-specific,
conformation-dependentmonoclonal antibodyW6/32was used to
capture peptide-loaded HLA complexes. Noncovalent interactions
among the complex components were abolished by acid treatment,
eluted peptides were separated by reverse-phase HPLC from the
α-chain and β2-microglobulin of the HLA complexes and the eluted
peptide fractions were analyzed by LC-MS/MS. Collected spectra
were interpreted using PEAKS and MASCOT utilizing a protein
database that included translations of all the six open reading
frames of the complete genomic sequence and annotated protein
sequences of the HIV-1 IIIB stock used for infections.
A range between 2416 and 6795 unique peptides was identi-
fied in the C8166 and C6, C7, and C8 cell samples (Fig. 1A), of
which 75 unique peptides (1.1%) in total were derived from HIV-1
(Table 1); no HIV-1-derived peptides were identified in mock-
infected cells. Although the peptides ranged from 5 to 52 amino
acids in length, 78–92% of peptides were 8–12 amino acids long
and 9-mers were overall themost abundant species (Fig. 1B). Long
peptides could be originated fromHLA complexes in the ER, which
are estimated to be 5–10% of the total HLA complex population
of the cell [13]. In addition, HLA-bound peptides longer than 12
and up to 25 amino acids have been characterized in the context
of several HLA class I alleles [14–16].
For the primary infected cell line samples, sequence alignment
of all identified 9-mer peptides broadly confirmed an enrichment
of the predicted amino acids in the anchor residue positions for
the HLA allele genotype of the regarding sample (Fig. 1C) [17].
The eluted HIV-1 peptides were of the following origins: 38
(51%) were from Gag; 9 (12%) were from Pol; 16 (21%) were
from Env; 5 (7%) were from Nef; 3 (4%) were from Rev, and
3 (4%) were from Vpu (Fig. 1D and Table 1). Peptide SR11
(Table 1) originates from a protein translated from an alterna-
tive HIV-1 reading frame [18]. Overall, 21 (28%) peptides were
derived from conserved regions of the HIV-1 proteome (up to 6%
amino acid variation), which are common to many HIV-1 isolates
and, therefore, attractive vaccine targets [19]. Of the 75 identi-
fied HIV-1 peptide sequences, only 13 (17%) matched previously
identified optimal epitopes in the Los Alamos National Laboratory-
HIV Sequence Database (LANL-HIVDB) and only 9/13 were pre-
viously reported for the HLA haplotypes of analyzed samples. For
27 (36%) peptides, either a longer sequence containing the iden-
tified peptide sequence or a fragment of the identified peptide
was reported in LANL-HIVDB, and for 18/27 sequences an HLA
restriction matching one HLA allele of the haplotype analyzed was
reported. A further 9 (12%) peptides were reported with one or
two amino acid substitutions. The other 26 (35%) peptides were
C© 2015 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
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Figure 1. HLA class I-associated peptides from HIV-1-infected cells. The human T-cell line C8166 and primary CD4+ cells from three individuals
(samples C6, C7, C8) were infected with HIV-1 for 5–7 days. HLA class I-associated peptides were purified and analyzed using LC-MS/MS. (A) The
total numbers of unique peptide sequences identified by LC-MS/MS in each sample from a single immunopecipitation experiment with W6/32
antibody and (B) the length distributions of identified peptides in the C8166 cell line (left) and primary CD4+ cells (right) are shown. (C) Motif
analysis of all eluted 9-mer peptides for each of the HIV-1-infected samples (Weblogo 3.4 [17]). Known anchor residues for the relevant HLA-A and
HLA-B subtypes are listed above the graphs for each sample (information from MHC Motif Viewer [37, 38]). The size of the letter representing the
amino acid in the indicated position is scaled according to the frequency of occurrence in the peptide. (D) Schematic overview of all HIV-1-derived
immunopeptides identified in the samples relative to the position of the HIV-1 proteins assigned within the viral genome, which are depicted as
gray boxes. Numbers above and below the gray bars indicate the nucleotide position of the starts and ends of the regarding HIV-1 genes using the
strain HXB2 annotation (generated using the Los Alamos National Laboratory HIV Sequence Locator Tool). The position of each identified peptide
sequence relative to the position in the HXB2 annotation is indicated as vertical gray line in the rectangular panel depicted for each sample.
not previously mapped and were, therefore, considered novel.
Notably, peptide FY9 was identified in all three primary infected
T-cell lines irrespective of the distinct HLA haplotypes and may be
presented by a noncanonical HLA allele, i.e. HLA-E.
To experimentally affirm the correct assignment of the frag-
ment spectra to precursor peptide sequences, identified HIV-1-
derived peptides were synthesized and analyzed under identical
conditions by LC-MS/MS for spectrum matches. Of the 53 tested
peptides, spectra of 48 (91%) could be confidently matched to
those obtained from HIV-1-infected cells (Fig. 2, Table 1).
Using the NetMHCpan 2.8 MHC binding prediction algorithm
and a percentile rank threshold of 2% [20–23], 47 (62%) peptides
C© 2015 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
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were predicted to bind to one HLA allele expressed in the sample
(Table 1). Generally, the prediction for binding of longer, non-
standard peptides is more challenging and limited to the identifi-
cation of nested binding sequences. However, an extensive search
of predicted nested binding sequences within the eluted peptide
sequences increased the number of predicted binding sequences
to 63 (84%).
Peptide-specific responses in HIV-1-infected
individuals
A biological validation was performed by testing 70 peptides
in interferon (IFN)-γ ELISPOT assays for recognition by PBMCs
from 24 HIV-1-infected subjects with variable HIV-1 disease con-
trol. Careful selection of individuals ensured that all HLA alle-
les, from which HIV-1 peptides were eluted, were covered. Over-
all, a median (range) of 4 (0–15) tested peptides were recog-
nized per donor with a median (range) total magnitude of all
added responses of 1225 (0–21 470) spot-forming cells (SFC)/106
PBMCs (Fig. 3). A total of 23/24 patients shared at least one HLA
allele with the cells used for peptide elution and 21/24 individu-
als responded to at least one of the peptides, whereas only three
subjects failed to respond to any peptide (Fig. 3). One individual
without anyHLAmatch still showed recognition of one stimulatory
peptide, likely responding through alleles belonging to different
HLA supertype as described previously [24, 25] or through CD4+
T-cell recognition. The median (range) number of peptides rec-
ognized per individual was 4.9 (0–15) and 23/70 (32%) tested
peptides were not recognized by any individual (with or without
matching HLA allele). Peptide AW11 (Gag) was recognized by
12/24 subjects; this is an optimal epitope described in the LANL-
HIVDB restricted by HLA-C*05:01.
The rest of the eluted peptides were recognized between one
and six times. Importantly, most of the observed responses tar-
geted peptides that had not previously been defined as epitopes,
and only a small proportion of responses were specific for known
optimal epitopes. Of the peptides that did not match any HLA-
binding motif of the corresponding cell line, 50% (6/12) gave
T-cell responses, in contrast to a 71% (41/58) response rate for
peptides that did match at least one HLA-binding motif. For pep-
tides with predicted binding stronger than or equal to 0.1%, 83%
(10/12) gave a T-cell response.
Discussion
Changes in HLA-associated peptide presentation have been ana-
lyzed in the context of HIV-1 infection [26] and more recently,
HIV-1-specific, HLA-associated peptides have been identified in a
model cell line secreting HLA-A*11:01 molecules [11, 26], pro-
viding critical novel information for the definition of T-cell targets
in HIV-1 infection. However, the ability to define HLA-class I-
associated, HIV-1-derived peptidome directly from HIV-1-infected
primary cells allows a more precise view of the peptides presented
C© 2015 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 2. Spectral matches for HIV-1-derived peptides. HLA-associated viral peptides sequences were synthesized and measured by LC-MS/MS
under identical conditions as the experimentally identified peptide sequences. Shown here are examples for one peptide sequence identified in
each of the primary infected cell samples C6, C7, and C8. Both the experimental spectrum that was detected in the indicated sample and the
spectrum acquired from the synthetic counterpart (standard) are plotted relative to each other to illustrate the spectral match. Fragment ions are
labeled in the spectra and the regarding molecular fragment is indicated in the peptide sequence above each spectrum. Ions are labeled as follows:
b: singly charged N-terminal fragment ion; y: singly charged C-terminal fragment ion; o: loss of H2O; p: parent peptide ion. The detected mass to
charge ratio [m/z] of the intact peptide parent ion is stated for each spectrum shown.
on HIV-1-infected cells and facilitates detection of natural T-cell
targets.
In our analyses, 35% of eluted HIV-1-derived peptides had not
to date been reported to be presented by HLA class I and 83% of
the peptides had not been previously mapped to a precise HLA-
binding sequence. Underrepresentation of Pol-derived peptides
from primary infected CD4+ cells was notable and concurred with
some previous reports [27–29], these peptides may be less abun-
dantly presented on HLA-I molecules in infected cells compared
to Gag-derived peptides. However, the number of vaccine-elicited
Pol-specific CD8+ effectors has been shown to correlate with inhi-
bition of HIV-1 replication in autologous cells at least equally to
Gag-specific responses [30, 31]. Thirty-two percent of the eluted
peptides were not recognized in subjects used in this study that
were naturally infected with HIV-1. This could be because the
viruses with which these individuals were infected deviated from
the relevant sequences, or because responses mounted to these
peptides had declined to undetectable frequencies at the time of
sampling due to viral escape. Alternatively, responses to these
peptides may be subdominant to undetectable levels. On the other
hand, responses to some peptides may also not have been induced
due to a gap in T-cell repertoire or due to HLA restriction. Nev-
ertheless, vaccination may induce T-cell responses against these
peptides and therefore these sequences remain to be useful targets
for T-cell vaccination.
In conclusion, we demonstrate here that we now have the
capacity to delve more deeply into the HLA class I-associated
immunopeptidome of primary infected cells to identify less-
abundant pathogen-derived peptides. These advances bring us one
step further toward identification of T-cell targets on primary cells
isolated from infected individuals in a clinical setting which will
be of exceptional importance for the development of personalized
immune treatments.
Materials and methods
HIV-1 IIIB virus stock preparation
HIV-1 IIIB (clade B, CXCR4-tropic) isolate was obtained from the
Program EVA Centre for AIDS Reagents, National Institute for Bio-
logical Standards and Control (NIBSC) and expanded as described
previously [12]. HIV-1 IIIB viral stocks were prepared by propaga-
tion in primary CD4+ cells and virus-containing supernatant was
harvested at day 6 postinfection, aliquoted, and frozen at −80°C.
Fifty percent tissue culture infectious dose (TCID50) was calcu-
lated as described previously [12].
Cell culture
C8166 cells or CD4+ T cells purified from PBMC by magnetic bead
selection were stimulated with phytohemagglutinin (5 μg/mL)
in RPMI-1640 medium supplemented with 10% FCS (R10) for 3
days, washed, and infected with HIV-1 IIIB at a MOI of 0.01. This
preselected MOI yielded detectable infection in all wells when
tested in the TCID50 assay without causing significant cell death,
i.e. less 20% lymphocytes stained with Aqua Live/Dead (Invitro-
gen, data not shown). Infection was achieved by spinoculation for
2 h at 25°C, after which cells were washed twice and cultured at
1.5 × 106 cells/mL in R10 supplemented with IL-2 (20 IU/mL) for
5–7 days before harvesting the cells. To estimate the percent infec-
tion, 0.5 × 106 cells were harvested and stained first with Aqua
Live/Dead Fixable stain (Invitrogen), fixed with 4% paraformalde-
hyde solution/lysolecithin (20 μg/mL) at room temperature and
resuspended in cold 50% methanol for 15 min. Further permeabi-
lization was achieved with 0.1% Nonidet P-40 and cells were then
C© 2015 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 3. T-cell responses to eluted HIV-1
peptides identified in HIV-1-infected sub-
jects. PBMCs from 24 HIV-1 positive individ-
uals were screened for T-cell responses to
the identified peptide sequences by deter-
mining IFN-γ output in an ELISPOT assay.
For each patient, the number of recog-
nized peptides (breadth of the response)
and the total magnitude of T-cell responses
are shown in the graph. The HLA genotype
of all six class I alleles for HLA-A, -B, and -C
is given below each patient ID number. Alle-
les matching any of the alleles of the C8166
cell line or the three primary cell samples
analyzed are highlighted in green. For ref-
erence, a heat map illustrating responses to
each of the 70 peptide sequences tested is
shown below for each patient.
stained with antibodies to HIV-1- Gag p24 (KC-57-FITC, Beckman
Coulter) followed by antibodies to CD3, CD4, and CD8 conjugated
to APC-Cy7, PerCP, and APC, respectively (BD Biosciences). Sam-
ples were acquired on a CyAn flow cytometer and analyzed using
FlowJo (version 9.2). If the infection rates were equal or above
20% of CD4+CD3+ live cells, cells were harvested and lysed using
cell lysis buffer (1% Igepal 630, 300 mM NaCl, 100 mM Tris pH
8.0). Intracellular p24 was detected after NP-40 permeabilization
and staining with a HIV-1 Gag p24-specific antibody (KC-57).
HLA class I immunoprecipitation and HPLC
fractionation
Purification of HLA class I-bound peptides was carried out as previ-
ously described [32]. Briefly, lysates of infected cells were cleared
by two subsequent centrifugation steps at 500 × g for 10 min and
20.000 × g for 30 min. HLA complexes were captured on Protein
A-sepharose beads (Expedeon) cross-linked to W6/32 antibody
(5 mg/mL) [32] at gravity flow and washed using subsequent
runs of 50 mM Tris buffer, pH 8.0 containing first 150 mM NaCl,
then 400 mM NaCl, and then, no salt. HLA-peptide complexes
were eluted with 5 mL 10% acetic acid. Affinity column-eluted
material was loaded onto on a 4.6 × 50 mm ProSwift RP-1S col-
umn (Thermo Fisher Scientific) and eluted using a 500 μL/min
flow rate over 10 min from 2 to 35% buffer B (0.1% formic acid
in acetonitrile) in buffer A (0.1% formic acid in water) using an
Ultimate 3000 HPLC system (Thermo Scientific). Detection was
performed using a variable wavelength detector at 280 nm. Frac-
tions up to 12 min that did not contain ß2-microglobulin were
combined and dried.
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LC-MS/MS analysis
Each sample was resuspended in 20 μL buffer A and analyzed
both on an Orbitrap Elite (Thermo Scientific) online coupled to an
Acquity nano UPLC (Waters) and a TripleTOF 5600 (AB SCIEX)
coupled to an Eksigent ekspert nanoLC 400 cHiPLC system. Orbi-
trap Elite: Peptides were separated on a nano Acquity UPLC system
(Waters) supplemented with a 25 cm BEH130 C18 column, 1.7-
mm particle size using a linear gradient from 8 to 35% buffer B
in buffer A at a flow rate of 250 nL/min for 60 min. Peptides
were introduced to an Orbitrap Elite mass spectrometer using a
nanoESI source. Subsequent isolation and collision-induced dis-
sociation was induced on the 20 most abundant ions per full MS
scan using an isolation width of 1.5 amu. All fragmented precur-
sor ions were actively excluded from repeated selection for 15 s.
TripleTOF 5600: Peptides were separated on an ekspert nanoLC
400 cHiPLC system (Eksigent) supplementedwith a 15 cm x 75μm
ChromXP C18-CL, 3 μm particle size using a linear gradient from
8% buffer A to 35% buffer B at a flow rate of 300 nL/min for 60
min. Peptides were introduced to TripleTOF 5600mass spectrome-
ter and collision-induced dissociation fragmentation using ramped
collision energy was induced on the 30 most abundant ions per
full MS scan using unit isolation width 0.7 amu. All fragmented
precursor ions were actively excluded from repeated selection
for 15 s.
MS data analysis interpretation
Raw data were converted to MASCOT generic files using mscon-
vert [33] or ProteinPilot 4.5 [34]. Sequence interpretation of
MS/MS spectra were performed using a database containing all
annotated human SwissProt entries including translations of all
six reading frames of the sequenced HIV-1 IIIB genome in addi-
tion to translations of all known assigned HIV-1 protein cod-
ing regions (GenBank KJ925006) or a database containing all
annotated human SwissProt entries (02/2013, 20 253 entries)
and all HIV-1 entries in NCBI (02/2013, 446 954 entries) with
PEAKS 7 [33] and MASCOT 2.4 [34, 35]. The probability score
threshold was defined by decoy database searches implemented
in the regarding search engines at a general false discovery rate
of 5%.
Ethics statement
Chronically HIV-1-infected individuals were recruited from the
HIV Unit in Hospital Germans Trias i Pujol, Badalona (n = 16)
and Hospital de la Vall d’Hebron, Barcelona, Spain (n = 8). The
study was approved by the Institutional Review Board of both par-
ticipating hospitals and all individuals provided written informed
consent before entering the study. PBMC samples were drawn and
processed within 4 h after venipuncture and the cells were stored
in liquid nitrogen until use.
IFN-γ ELISPOT assay
IFN-γ ELISPOT assay was performed as previously described
[24, 36]. A screening for CTL responses was developed using a
matrix of 70 eluted peptides from immunoprecipitated HLA class
I complexes. Cryopreserved PBMCs from 24 subjects were incu-
batedwith thematrix peptide pools in a precoated plate (Millipore,
Barcelona, Spain) with anti-human IFN-γ monoclonal antibody
(Mabtech, Sweden). Cells with R10 medium only were used as
negative controls and cells with phytohemagglutinin were used
as positive controls. PBMCs were cultured overnight at 37°C,
5% CO2 atmosphere, and then washed six times with PBS. The
plates were then incubated for 1 h at room temperature with
the biotinylated anti-I IFN-γ monoclonal antibody (Mabtech) fol-
lowed by six washes and 1 h incubation with the streptavidin-
coupled alkaline phosphatase (Mabtech). After washing the plate,
nitro blue tetrazolium and 5-bromo-4-chloro-3-indolul phosphate
(Bio-Rad, Barcelona, Spain) were added for color development.
After a short incubation, the reaction was stopped by washing
the plate with tap water. The IFN-γ production was detected as
blue spots on the membrane, the spot-forming units were counted
with an automated ELISPOT reader system (CTL, Germany) using
ImmunoSpot software package. Responses were defined as posi-
tive if they exceeded (i) 50 spot-forming units/106 PBMC per well,
(ii) the mean of negative wells plus three standard deviations, and
(iii) three times the mean of the negative well, whichever was
higher.
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